Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

FMP2.1 Trial in Bandiagara, Mali

This study has been completed.
National Institute of Allergy and Infectious Diseases (NIAID)
Walter Reed Army Institute of Research (WRAIR)
University of Maryland
Information provided by (Responsible Party):
U.S. Army Medical Research and Materiel Command Identifier:
First received: July 6, 2006
Last updated: June 19, 2012
Last verified: June 2012
Malaria is a disease that affects many people in Africa and in Mali. It is caused by germs that are spread by mosquito bites. This study will look at the safety, effectiveness, and best dose of an experimental malaria vaccine in people who are regularly exposed to malaria. Study participants will be 60 adults, 18-55 years old, who live in Bandiagara, Mali. Volunteers will get either 3 full doses of the experimental malaria vaccine, 3 half doses of the malaria vaccine, or a rabies vaccine that has been approved in Mali. (Rabies is an infection of the brain that usually causes death, and can be caught from being bitten by infected dogs or bats.) The 3 vaccinations will be given by injection into the upper arm 30 days apart. Volunteers will be enrolled in the study for approximately 12 months after the first vaccination. Volunteers will have 14 blood samples collected during the study for testing to make sure that the vaccine is not harmful and to measure the effect of the vaccine.

Condition Intervention Phase
Plasmodium Falciparum Malaria
Biological: FMP2.1/AS02A
Biological: Rabies vaccine
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Double Blind Randomized, Controlled Phase 1 Dose Escalation Trial to Evaluate the Safety and Immunogenicity of the WRAIR AMA1 Malaria Antigen (FMP2.1) Adjuvanted in GSK's AS02A Versus Rabies Vaccine in Malaria-experienced Adults in Bandiagara, Mali

Resource links provided by NLM:

Further study details as provided by U.S. Army Medical Research and Materiel Command:

Primary Outcome Measures:
  • Safety and reactogenicity [ Time Frame: ongoing ]
    The primary objective was to evaluate the safety and reactogenicity of 2 dose levels of WRAIR's AMA1 malaria antigen (FMP2.1) adjuvanted in GlaxoSmithKline Biologicals' (GSK) AS02A compared to rabies vaccine in malaria-experienced Malian adults aged 18-55 years inclusive.

Enrollment: 60
Study Start Date: November 2004
Study Completion Date: December 2006
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: FMP2.1
FMP2.1 vaccine
Biological: FMP2.1/AS02A
Placebo Comparator: Rabies vaccine
Rabies vaccine
Biological: Rabies vaccine

Detailed Description:
The primary objective of this study is to evaluate the safety and reactogenicity of two dose levels of WRAIR's AMA1 malaria antigen (FMP2.1) adjuvanted in GlaxoSmithKline Biologicals' AS02A compared to rabies vaccine in malaria-experienced Malian adults aged 18-55 years inclusive. Secondary objectives are to: (1) measure the magnitude and duration of antibody response to FMP2.1; (2) measure cellular immune responses to FMP2.1 at baseline and after immunization; (3) measure the inhibition of parasite growth by the in vitro GIA; and (4) determine the specificity of the antibodies to diverse AMA1 genotypes in addition to 3D7, by measuring by ELISA, and GIA on parasites with typed AMA1. A double-blind controlled dose escalation trial will allow assessment of vaccine safety in each of three groups, one group each to receive medium and full dose levels of the experimental vaccine, and one group to receive the comparator vaccine. Thirty adults will be randomized to receive the medium dose level of FMP2.1 (n=20) or rabies vaccine (n=10) and thirty to receive the full dose level of FMP2.1 (n=20) or rabies vaccine (n=10). The division of the rabies group into two groups of ten is done to maintain blinding at each immunization time point, and all participants who receive the rabies vaccine will be analyzed as a single group. The sample size of the groups, however, will not allow detection of anything other than very large differences in the occurrence of adverse events among the three groups. The advantage of double blinding is to remove the potential for investigator and participant prejudgment about the effects of the vaccines in the reporting of adverse events.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. A male or non-pregnant female aged 18-55 years inclusive at the time of screening
  2. For women, willingness not to become pregnant until 1 month after the last immunization (pre-menopausal female participants will be referred to the local family planning clinic in Bandiagara, which offers several means of contraception that are approved and recommended by the Malian Ministry of Health)
  3. Separate written informed consent obtained from the participant before screening and study start, respectively
  4. Available and willing to participate in follow-up for the duration of study (12 months)

Exclusion Criteria:

  1. Previous vaccination with any investigational vaccine or with any rabies vaccine
  2. Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first study immunization, or planned use up to 30 days after the third immunization
  3. Chronic administration (defined as more than 14 days) of immuno-suppressants or other immune-modifying drugs within six months prior to the first immunization. This will include any dose level of oral steroids or inhaled steroids, but not topical steroids
  4. Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before the first study immunization with the exception of tetanus toxoid
  5. Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection
  6. Any confirmed or suspected autoimmune disease
  7. History of allergic reactions or anaphylaxis to immunizations or to any vaccine component
  8. History of serious allergic reactions to any substance, requiring hospitalization or emergent medical care
  9. History of allergy to tetracycline, doxycycline, nickel, Imidazole, chicken eggs, processed bovine gelatin, chicken protein, neomycin, or amphotericin B
  10. History of splenectomy
  11. Serum ALT >/=43 IU/L
  12. Serum creatinine level >113 µmol /L for males and 70 µmol /L for females
  13. Hgb <11 g/dL for males and <10 g/dL for females
  14. WBC <4.0 x 1000/cubic mm or >13 x 1000/cubic mm
  15. Absolute lymphocyte count </=1.4 x 1000 /µl
  16. Thrombocytopenia < 108,000/µl
  17. More than trace protein, more than trace hemoglobin or positive glucose in urine
  18. Administration of immunoglobulins and/or any blood products within the three months preceding the first study immunization or planned administration during the study period
  19. Suspected or known current alcohol or illicit drug abuse
  20. Pregnancy or positive urine beta-HCG on the day of or prior to immunization
  21. Breastfeeding
  22. Simultaneous participation in any other interventional clinical trial
  23. Acute or chronic pulmonary, cardiovascular, hepatic, renal or neurological condition, or any other findings that in the opinion of the Principal Investigator (PI) may increase the risk of participating in the study
  24. Other condition that in the opinion of the PI would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00349713

University of Bamako, Malaria Research and Training Center
Bamako, Mali
Sponsors and Collaborators
U.S. Army Medical Research and Materiel Command
National Institute of Allergy and Infectious Diseases (NIAID)
Walter Reed Army Institute of Research (WRAIR)
University of Maryland
Principal Investigator: Mahamadou A. Thera, M.D. University of Bamako
Principal Investigator: Chris V. Plowe, M.D. University of Maryland
  More Information

Responsible Party: U.S. Army Medical Research and Materiel Command Identifier: NCT00349713     History of Changes
Other Study ID Numbers: 04-031
N01AI085346-010 ( NIH Grant/Contract Number )
N01AI085346-009 ( NIH Grant/Contract Number )
N01AI085346-007 ( NIH Grant/Contract Number )
N01AI085346-006 ( US NIH Grant/Contract Award Number )
N01AI085346-005 ( US NIH Grant/Contract Award Number )
N01AI085346-000 ( US NIH Grant/Contract Award Number )
102231 ( Malaria-037) ( Other Identifier: GSK )
HSRRB A-12855 ( Other Identifier: USAMRMC )
Study First Received: July 6, 2006
Last Updated: June 19, 2012

Keywords provided by U.S. Army Medical Research and Materiel Command:
Plasmodium falciparum Malaria, Mali, adjuvant

Additional relevant MeSH terms:
Malaria, Falciparum
Protozoan Infections
Parasitic Diseases
Immunologic Factors
Physiological Effects of Drugs processed this record on May 25, 2017